---

Disclaimer: This information is provided for educational purposes and is modeled after clinical reference tools. It is not a substitute for the independent professional judgment of a healthcare provider. Clinical decisions must always be tailored to the individual patient, considering their specific situation, comorbidities, and current best practices. Dosages and guidelines are subject to change; always verify with current, authoritative sources.

---

Diabetes Mellitus

Overview

• Definition: Diabetes Mellitus (DM) is a heterogeneous group of metabolic disorders characterized by sustained hyperglycemia resulting from defects in insulin secretion, insulin action, or both. Chronic hyperglycemia is associated with damage to multiple organ systems, particularly the kidneys, eyes, nerves, and cardiovascular system.

• Epidemiology:

  • Prevalence: Approximately 11.3% of the US population (over 37 million people) has DM (CDC, 2022).
  • Undiagnosed: About 20% of cases remain undiagnosed.
  • Global Impact: Over 537 million adults globally have DM (IDF, 2021).
  • Demographics: Type 2 DM (T2DM) rates are disproportionately higher in certain ethnic groups (e.g., African Americans, Hispanics, Native Americans, Asian Americans). T1DM incidence is increasing, particularly in younger children.

• Classification:

  1. Type 1 Diabetes Mellitus (T1DM): Autoimmune destruction of pancreatic beta cells, usually leading to absolute insulin deficiency. Accounts for 5–10% of cases. Typically develops in childhood/adolescence (though LADA is T1DM presenting in adulthood).
  2. Type 2 Diabetes Mellitus (T2DM): Progressive loss of $\beta$-cell insulin secretion often coupled with insulin resistance. Accounts for 90–95% of cases.
  3. Gestational Diabetes Mellitus (GDM): Diabetes diagnosed in the second or third trimester of pregnancy that was not overtly diabetic prior to gestation.
  4. Other Specific Types: Monogenic diabetes (e.g., MODY, neonatal diabetes), diseases of the exocrine pancreas (e.g., pancreatitis, cystic fibrosis), and drug- or chemical-induced diabetes (e.g., glucocorticoids, post-transplant).

Pathophysiology

• Mechanism:

  • T1DM: Immune-mediated destruction of pancreatic islets, often involving autoantibodies (e.g., anti-GAD65, anti-ICA, anti-insulin). Leads to insufficient insulin production to regulate glucose.
  • T2DM: Characterized by a combination of:
    1. Insulin Resistance: Reduced sensitivity of peripheral tissues (muscle, fat, liver) to insulin action.
    2. Relative Insulin Deficiency: $\beta$-cell dysfunction and failure, leading to insufficient insulin output to overcome resistance. The Incretin Effect (GLP-1 and GIP) is also often impaired.
  • GDM: Placental hormones (e.g., human placental lactogen) cause increased insulin resistance, necessitating elevated insulin production; some women cannot compensate.

• Risk Factors:

  • T1DM: Family history, specific HLA haplotypes (DR3/DR4), exposure to certain viral infections (less defined).
  • T2DM: Age ($\ge 45$ years), overweight/obesity (BMI $\ge 25$ kg/m² or $\ge 23$ kg/m² in Asian Americans), physical inactivity, family history (first-degree relative), history of GDM or PCOS, hypertension (BP $\ge 140/90$ mmHg), dyslipidemia (HDL $\le 35$ mg/dL or triglycerides $\ge 250$ mg/dL), cardiovascular disease history.

• Protective Factors:

  • Maintenance of healthy body weight (BMI $18.5–24.9$ kg/m²).
  • Regular physical activity (e.g., $\ge 150$ minutes/week of moderate-intensity aerobic exercise).
  • Healthy diet rich in whole grains, fiber, and unsaturated fats (Mediterranean or DASH diet patterns).

Clinical Presentation

Signs and Symptoms

• Cardinal Features (Hyperglycemia/Osmotic Diuresis):

  • Polyuria (frequent urination)
  • Polydipsia (excessive thirst)
  • Polyphagia (excessive hunger – more common in T1DM)
  • Unexplained weight loss (especially T1DM)

• Early Signs: Fatigue, blurred vision, recurrent infections (skin, urinary tract, candidiasis), slow wound healing, paresthesias (early neuropathy).

• Advanced Signs (Associated with Poorly Controlled DM or Acute Crises):

  • Diabetic Ketoacidosis (DKA): Abdominal pain, nausea, vomiting, Kussmaul respirations (deep, labored breathing), fruity breath odor (acetone).
  • Hyperosmolar Hyperglycemic State (HHS): Severe dehydration, altered mental status, focal neurological deficits, stupor, coma.

• Atypical Presentations:

  • T2DM: Often asymptomatic and diagnosed incidentally via routine screening or presentation with a complication (e.g., myocardial infarction, non-healing foot ulcer, retinopathy).
  • LADA (Latent Autoimmune Diabetes in Adults): Often misdiagnosed as T2DM, but progresses more rapidly to insulin dependence.

Physical Examination

• Inspection:
  • Skin: Acanthosis nigricans (hyperpigmentation/velvety texture, neck/axillae—indicates insulin resistance), skin tags, chronic skin lesions, candidal infections, lipodystrophy (at insulin injection sites).
  • Eyes: Cotton wool spots, microaneurysms, hemorrhages (retinopathy), cataracts.
  • Feet: Evidence of foot ulcers, calluses, Charcot arthropathy (rocker-bottom deformity), absent hair, shin discoloration (diabetic dermopathy).
• Palpation:
  • Cardiovascular: Diminished peripheral pulses (peripheral artery disease).
  • Neurological: Loss of sensation (distal symmetric polyneuropathy) using monofilament testing.
• Special Tests:
  • 10-gram Monofilament Test: Essential for assessing peripheral neuropathy and risk of foot ulceration.
  • Tuning Fork (128 Hz): Assess vibratory sensation.
  • Light Touch/Pinprick: Assess tactile/pain sensation.
  • Fundoscopic Exam: Direct visualization of the retina for signs of retinopathy.

Diagnostic Approach

History Taking

• Key Questions:

  • Symptoms: Onset and severity of classic polyuria, polydipsia, weight loss, and fatigue.
  • Family History: DM, cardiovascular disease, hypertension.
  • Risk Factors: Weight changes, physical activity level, diet, tobacco/alcohol use.
  • Complications Screening: Visual changes, numbness/tingling (neuropathy), chest pain (CAD), intermittent claudication (PAD), recurrent infections, erectile dysfunction.
  • Prior History: History of GDM, large birth weight infant ($>9$ lbs), PCOS, steroid use.

• Red Flags (Suggesting Acute Crisis):

  • Persistent nausea, vomiting, or severe abdominal pain (DKA).
  • Altered mental status, severe confusion, or stupor (DKA or HHS).
  • Signs of severe dehydration (tachycardia, orthostasis, delayed capillary refill).
  • Severe, non-healing foot wound with signs of infection (sepsis risk).

Laboratory Tests

Diagnosis requires confirmation on a subsequent day (unless unequivocal hyperglycemia is present with classic symptoms or acute crisis).

• Diagnostic Criteria for DM (ADA 2024):

  1. HbA1c: $\ge 6.5\%$
  2. Fasting Plasma Glucose (FPG): $\ge 126$ mg/dL (after no caloric intake for $\ge 8$ hours)
  3. 2-hour Plasma Glucose (OGTT): $\ge 200$ mg/dL during an Oral Glucose Tolerance Test using 75g anhydrous glucose load.
  4. Random Plasma Glucose: $\ge 200$ mg/dL in a patient with classic symptoms of hyperglycemia or hyperglycemic crisis.

• Prediabetes (Increased Risk):

  1. HbA1c: $5.7\% – 6.4\%$
  2. FPG: $100$ mg/dL – $125$ mg/dL
  3. 2-hour OGTT: $140$ mg/dL – $199$ mg/dL

• First-Line: HbA1c and FPG.

• Confirmatory (If diagnosis is unclear): Oral Glucose Tolerance Test (OGTT).

• Subtype Differentiation (If T1DM is suspected):

  • C-peptide: Low or undetectable (indicates severe insulin deficiency).
  • Autoantibodies: Glutamic acid decarboxylase autoantibodies (GADA or anti-GAD65), Islet cell autoantibodies (ICA), Insulin autoantibodies (IAA).

• Monitoring (Established DM):

  • HbA1c: Routinely measured $\ge 2$ times a year if stable, or quarterly (every 3 months) if therapy is adjusted or glycemic control is suboptimal.
  • Lipid Panel: Annually (or more frequently if dyslipidemia is present).
  • Renal Function: Serum creatinine, GFR calculation, and Urine Albumin/Creatinine Ratio (UACR)—annually for T1DM duration $\ge 5$ years and all T2DM patients.
  • Comprehensive Metabolic Panel (CMP): Electrolytes, liver function tests.

Imaging

• Recommended:

  • Electrocardiogram (ECG): Baseline screening for silent ischemia, especially in high-risk patients.
  • Ankle-Brachial Index (ABI): Recommended for patients $\ge 50$ years or younger patients with risk factors to screen for PAD.

• Advanced (When Complications Are Suspected):

  • Ophthalmology Consultation: Annual dilated, comprehensive eye examination (retinopathy screening).
  • Cardiac Stress Testing: Used selectively if symptoms of CAD are present or if high-risk features exist prior to high-risk physical activity regimen.
  • Foot X-rays/MRI: If concern for osteomyelitis, Charcot arthropathy, or deep soft tissue infection.

Management

Acute Management: Hyperglycemic Crises

Condition	Primary Features	Immediate Intervention
Diabetic Ketoacidosis (DKA)	Hyperglycemia ($>250$ mg/dL), Metabolic Acidosis ($\text{pH} <7.3$; Bicarb $<18$ mEq/L), large Anion Gap ($\text{AG} >12$), Ketones in urine/blood.	FLUIDS ($\text{NS}$ 1-1.5 L/hour initially), INSULIN (IV regular bolus 0.1 U/kg, then infusion 0.1 U/kg/hr), POTASSIUM (Supplementation if $\text{K} < 5.2$ mEq/L, withhold insulin if $\text{K} < 3.3$).
Hyperosmolar Hyperglycemic State (HHS)	Severe Hyperglycemia ($>600$ mg/dL), Severe Dehydration, high effective Serum Osmolality ($>320 \text{ mOsm/kg}$), minimal/absent ketones, profound alteration in consciousness.	FLUIDS (More aggressive fluid replacement needed), INSULIN (IV infusion 0.1 U/kg/hr, start after fluids/potassium check), Electrolyte Correction.
Severe Hypoglycemia	Plasma Glucose $<54$ mg/dL. Altered mental status, seizures.	Unconscious: $\text{Glucagon}$ 1 mg IM or SubQ, or $50\%$ Dextrose (D50) $25$ g IV. Conscious: $15$–$20$ g fast-acting carbohydrates (e.g., glucose tablets, juice).

Chronic Management

• Glycemic Goals (ADA 2024):
  • General Goal: HbA1c $<7.0\%$ (to reduce microvascular complications).
  • Less Stringent: HbA1c $<8.0\%$ or $<8.5\%$ in patients with limited life expectancy, extensive comorbidities, or history of severe hypoglycemia.
  • More Stringent: HbA1c $<6.5\%$ in select patients (young, healthy, newly diagnosed, no significant CVD/hypoglycemia risk).

Pharmacological (T2DM)

The ADA/EASD consensus prioritizes agents with proven cardiovascular and renal benefits, particularly in patients with atherosclerotic cardiovascular disease (ASCVD), high ASCVD risk, heart failure (HF), or chronic kidney disease (CKD).

Class	Mechanism of Action	Key Benefits/Dosing Considerations
Metformin	Decreases hepatic glucose production, improves insulin sensitivity.	First-line unless contraindicated. Dose: Start 500 mg daily, titrate to 1000 mg BID (Max 2550 mg/day). Needs monitoring of eGFR (contraindicated if eGFR $<30$).
SGLT2 Inhibitors (-gliflozin) (e.g., Empagliflozin, Dapagliflozin)	Inhibits glucose reabsorption in the proximal tubule (glucose excretion).	Proven CV and renal protection (CKD progression, HF hospitalization). Side effects: GU infections, volume depletion, risk of euglycemic DKA (rare).
GLP-1 Receptor Agonists (-glutide) (e.g., Semaglutide, Liraglutide, Dulaglutide)	Enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying.	Proven CV benefit (ASCVD risk reduction) and significant weight loss. Often preferred injectable agent. Administered weekly/daily (SubQ) or oral (Semaglutide).
DPP-4 Inhibitors (-gliptin) (e.g., Sitagliptin, Linagliptin)	Inhibits breakdown of incretins, modestly improving glucose control.	Neutral effect on weight/CVD. Good add-on, generally well-tolerated. Avoid in patients with history of pancreatitis.
Sulfonylureas (e.g., Glipizide, Glimepiride)	Stimulates insulin secretion (insulin-independent of glucose levels).	High risk of hypoglycemia, modest weight gain. Used cautiously, usually reserved for low-cost option if other agents contraindicated.
Thiazolidinediones (TZDs) (-glitazone) (e.g., Pioglitazone)	Increases insulin sensitivity in peripheral tissues.	Risk of weight gain, edema, and HF. Potential bone fracture risk. Contraindicated in NYHA Class III/IV HF.

• Insulin Therapy (T1DM and T2DM requiring replacement):
  • T1DM: Requires basal (long-acting) and prandial (rapid-acting) insulin coverage. Total daily dose (TDD) often $0.4–1.0$ U/kg/day, typically split 50% basal and 50% bolus, adjusted based on carb counting and blood glucose monitoring.
  • T2DM: Often initiated with basal insulin (e.g., Glargine, Detemir) $10$ units at bedtime or $0.1-0.2$ U/kg/day, titrated up. If A1c remains high, switch to a basal-bolus regimen or incorporate pre-mixed insulin.

Non-Pharmacological

• Medical Nutrition Therapy (MNT): Individualized approach. Focus on carbohydrate quality (fiber-rich, non-starchy vegetables) and consistency. Referrals to Registered Dietitian Nutritionists (RDNs) are mandatory.
• Physical Activity: $\ge 150$ minutes/week of moderate-intensity (e.g., brisk walking) or 75 minutes/week of vigorous-intensity aerobic physical activity. Incorporate resistance training $\ge 2$ days/week.
• Weight Management: Goal is $5–10\%$ sustained weight loss. Bariatric surgery is recommended for medically eligible T2DM patients with BMI $\ge 40$, or BMI $35.0–39.9$ when non-surgical therapies fail.

Treatment Algorithms (T2DM)

Step 1: Baseline Therapy Initiate lifestyle modification and Metformin (unless contraindicated).

Step 2: Dual Therapy (Add-on) If HbA1c target is not met after 3 months:

1. Patient with Established ASCVD, High Risk, HF, or CKD?
   • Yes: Add SGLT2i (preferred for HF/CKD) or GLP-1 RA (preferred for ASCVD risk reduction/weight loss). Continue Metformin.
   • No: Choose agent based on key goal:
     • Weight Loss/Obesity: GLP-1 RA or SGLT2i.
     • Cost Issues: Sulfonylurea or TZD.
     • Minimize Hypoglycemia: GLP-1 RA, SGLT2i, or DPP-4i.

Step 3: Triple Therapy and Intensification If target still not met: Add a third agent (e.g., Metformin + GLP-1 RA + SGLT2i).

Step 4: Consider Injectable Therapy (If not already used) If non-insulin therapies fail to achieve target A1c. 1. Basal Insulin Initiation: Usually $10$ U/day or $0.1-0.2$ U/kg/day, titrated every few days based on FPG targets. 2. Intensification: Add a prandial insulin injection (Basal-plus) or switch to a fixed-ratio combination (GLP-1 RA/Insulin) or full basal-bolus regimen.

Complications

Category	Common Examples	Serious/Life-Threatening Examples
Microvascular	Diabetic Retinopathy (leading to blindness), Diabetic Nephropathy (leading to ESRD, $30-40\%$ of new ESRD cases), Diabetic Neuropathy (distal symmetric polyneuropathy, autonomic neuropathy).	Hypoglycemia unawareness (autonomic neuropathy), Acute Kidney Injury.
Macrovascular	Cardiovascular Disease (CAD, MI, angina), Cerebrovascular Disease (stroke), Peripheral Artery Disease (PAD).	Acute Myocardial Infarction, Ischemic Stroke, Critical Limb Ischemia/Amputation.
Acute	Hypoglycemia, DKA, HHS, Infections (cellulitis, UTIs, fungal).	Severe Sepsis/Septic Shock.
Long-term	Diabetic foot ulcers, Gastroparesis, Cataracts/Glaucoma, Increased risk of certain cancers, Cognitive decline.	End-Stage Renal Disease (ESRD) requiring dialysis/transplant.

Prognosis

• Factors:

  • Poor Control: Chronic sustained hyperglycemia dramatically increases the risk of microvascular and macrovascular complications.
  • Comorbidities: Presence of hypertension, dyslipidemia, and ASCVD significantly worsens prognosis.
  • Age of Onset: Earlier onset of T1DM or T2DM is associated with reduced life expectancy due to prolonged exposure to risk.
  • Intervention: Intensive glycemic, lipid, and blood pressure control significantly improves long-term outcomes (demonstrated by studies like DCCT/EDC, UKPDS, ADVANCE, VADT).

• Survival: Life expectancy is generally reduced by an average of 6-10 years in patients with T2DM, largely driven by cardiovascular deaths. T1DM patients face higher mortality risk from acute complications (DKA, hypoglycemia) and accelerated vascular injury.

• Quality of Life: Poorly controlled DM significantly impairs QoL due to chronic symptoms (fatigue), anxiety about hypoglycemia, neuropathy pain, visual impairment, functional limitations from amputation, and depression/distress.

Prevention

• Primary (Preventing Initial Occurrence of T2DM):

  • Diet and Exercise: Intensive lifestyle modification (like the Diabetes Prevention Program - DPP) reduces T2DM incidence by $58\%$ in high-risk individuals (those with prediabetes). Goal: $\ge 7\%$ body weight loss and $\ge 150$ minutes/week physical activity.
  • Pharmacologic: Metformin 850 mg BID may be used for T2DM prevention in high-risk individuals (BMI $\ge 35$, age $<60$, and/or previous GDM), reducing incidence by $31\%$.

• Secondary (Early Detection and Intervention):

  • Screening: Annual screening for T2DM should begin at age 45, or earlier if overweight/obese (BMI $\ge 25$ kg/m²) and have one or more additional risk factors.
  • Treating Prediabetes: Implement lifestyle changes and monitor annually.

• Tertiary (Preventing Complications):

  • A, B, C, D, E Approach:
    • A: $\text{HbA1c}$ optimization (target $<7.0\%$)
    • B: Blood Pressure control (target $<130/80$ mmHg for most adults; individualize based on comorbidities)
    • C: Cholesterol management (High intensity statins for all DM patients aged 40–75 without ASCVD)
    • D: Diet, Drug efficacy (medication adherence), Depression
    • E: Eye and Extremity (annual foot and eye exams, smoking cessation).

Special Populations

• Pediatric (T1DM/T2DM):

  • T1DM: Requires high-level education, intensive insulin management, psychosocial support. A1c goal for most children is $<7.0\%$, but aims should be individualized to minimize hypoglycemia.
  • T2DM: Requires early education on lifestyle changes. Metformin is first-line drug therapy. Addition of insulin, or GLP-1 RA (Liraglutide, Semaglutide) if needed.

• Geriatric:

  • Focus shifts from strict A1c targets to avoidance of hypoglycemia and maintenance of quality of life.
  • Goals: Less stringent (A1c $<7.5\%$ to $<8.5\%$) depending on health complexity, functional status, and comorbidities.
  • Caution: Medication simplification, avoidance of high-risk drugs (e.g., long-acting sulfonylureas), and screen for cognitive impairment/frailty.

• Pregnancy (GDM):

  • Screening: Universal screening at $24–28$ weeks gestation (one-step [75g OGTT] or two-step [50g screen, 100g diagnostic] approach).
  • Goals: Strict glycemic control required: Fasting $\le 95$ mg/dL; 1-hour post-meal $\le 140$ mg/dL; 2-hour post-meal $\le 120$ mg/dL.
  • Treatment: First-line is MNT. Insulin is the preferred pharmacological agent; Metformin and Glyburide are used cautiously (not typically first-line).

• Comorbidities:

  • CKD/Nephropathy: Use of SGLT2i (e.g., Dapagliflozin, Farxiga—proven to slow CKD progression) and GLP-1 RA. ACE inhibitors or ARBs are mandatory for management of hypertension and albuminuria (target UACR reduction).
  • HF: SGLT2i are strongly indicated for reducing hospitalization risk associated with heart failure (HFrEF and HFpEF). TZDs are contraindicated.

Clinical Pearls

• Diagnostic: $\text{HbA1c}$ can be falsely low in conditions that shorten erythrocyte lifespan (e.g., hemolysis, chronic blood loss) and falsely high in iron deficiency anemia. Fructosamine or continuous glucose monitoring data may be necessary in these situations.
• Treatment: Never miss the opportunity to prescribe an SGLT2i or GLP-1 RA to a patient with comorbid ASCVD, CKD, or HF, regardless of their current A1c (due to their direct organ-protective benefits).
• Pitfalls:
  1. Therapeutic Inertia: Failing to intensify pharmacotherapy within a reasonable timeframe (3–6 months) when A1c targets are not met.
  2. Missing T1DM: Misdiagnosing adult-onset T1DM (LADA) as T2DM, leading to delayed insulin initiation and risks of DKA. If weight loss is rapid and management is challenging, check C-peptide/autoantibodies.
  3. Mismanaging Sick Days: Failing to educate patients on increasing fluid intake, continuing basal insulin (never stop!), and checking blood glucose/ketones more frequently during illness.

Recent Updates

• Guidelines (ADA 2024): Reinforced the primacy of SGLT2i and GLP-1 RAs in T2DM risk-based management pathways, emphasizing their cardiovascular and kidney benefits over traditional agents like sulfonylureas.
• Evidence (STEP/SELECT Trials): Demonstrated profound weight loss and cardiovascular event reduction with newer high-efficacy GLP-1 RAs/Dual Agonists (e.g., tirzepatide, high-dose semaglutide), positioning them as critical metabolic and cardiovascular therapies.
• Controversies: Optimal A1c goal for elderly and frail patients remains debated, generally favoring less strict control (A1c 8.0–8.5%) to prioritize hypoglycemia avoidance and quality of life over microvascular risk reduction.

Key References

• Guidelines:
  • American Diabetes Association (ADA) – Standards of Care in Diabetes (annual publication).
  • European Association for the Study of Diabetes (EASD) guidelines.
  • American Association of Clinical Endocrinology (AACE) guidelines.
• Studies:
  • UKPDS (UK Prospective Diabetes Study): Landmark study establishing the benefit of intensive glycemic and blood pressure control in newly diagnosed T2DM.
  • DCCT/EDIC (Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications): Established the benefit of intensive glycemic control in T1DM.
  • EMPA-REG OUTCOME/DECLARE-TIMI 58/CANVAS: Trials establishing CV and renal benefits of SGLT2 inhibitors.
  • LEADER/HARMONY/SUSTAIN-6: Trials establishing CV benefits of specific GLP-1 Receptor Agonists.
• Reviews: Major medical textbooks (e.g., Harrison's Principles of Internal Medicine), UpToDate, and reviews published in Diabetes Care and Lancet.